Poster in AACC 2011: Evidence for processing of human pro-B-type natriuretic peptide in the circulation.
Download document here:
Evidence for processing of human pro-B-type natriuretic peptide in the circulation.
Please click the link above to see the whole poster.
Alexander G. Semenov 1, Karina R. Seferian 1, Natalia N. Tamm 1, Anastasia V. Bereznikova 1, Marina M. Artem'eva 2, Andrey N. Kara 3, Alexander B. Postnikov 1, Alexey G. Katrukha 1.
B-type Natriuretic Peptide (BNP) is a circulating hormone primarily produced by the myocardium in response to volume overload and increased filling pressure. BNP is produced as a 108-amino acid residue (AAR) precursor molecule, proBNP. Cleavage of proBNP gives rise to the active BNP hormone (32 AAR) and N-terminal fragment, NTproBNP (76 AAR). Increased plasma concentrations of BNP and NT-proBNP as well as proBNP have been shown to be associated with the onset of heart failure (HF). In contrast to the clinical utility of proBNP-derived peptides, the data regarding proBNP processing is rather limited. So still it is no clear where proBNP processing takes place. The presence of proBNP in plasma led us to hypothesize that proBNP is processed in circulation. The goal of the present study was to examine this hypothesis.
Conclusions:
The present study shows that proBNP is processed in the circulation with formation of mature BNP 1-32. This observation suggests that the circulation can be considered as a place where proBNP processing occurs. Further studies are needed to demonstrate the relevance of these animal-based experiments to humans.
